<DOC>
	<DOC>NCT00259883</DOC>
	<brief_summary>This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received Benzodiazepines for at least 4 weeks, and changes in the symptoms of depression will be evaluated by use of the rate and extent of decrease in Hamilton Rating Scale for Depression (HAM-D).</brief_summary>
	<brief_title>Combination Of PAXIL Tablet And Benzodiazepines</brief_title>
	<detailed_description />
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Inclusion criteria: Patients with depression or depressive episodes who are diagnosed to have major depressive disorders according to the DSMIV criteria. Patients with 14 or higher points in total scores for Items No.1 17 on HAMD. Patients who have continuously received Benzodiazepine anxiolytics. Exclusion criteria: Patients with a strong suicide tendency.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>depressive episodes</keyword>
	<keyword>paroxetine</keyword>
	<keyword>PAXIL</keyword>
	<keyword>depression</keyword>
	<keyword>benzodiazepine</keyword>
	<keyword>combination</keyword>
</DOC>